Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy.

Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborators: Aarhus University Hospital; Aarhus University Hospital Skejby; Forskningsrådet for Sundhed og Sygdom; The Research Council for Health and Disease, Denmark
• Treatments: Insulin; Lanreotide; Octreotide; Somatostatin

Criteria

Inclusion Criteria:

• Age > 18

• Diagnosed with acromegaly

• Safe anticonceptive for fertile women

• Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH < 0.5 µg/l.)

Exclusion Criteria:

• Pregnancy

• Liver disease

• Diabetes mellitus type I

• Magnetic or electronic implants